Adial Pharmaceuticals adjourns votes on Nasdaq-dependent proposals
The company adjourned votes on Proposals 3–6 at its 2026 annual meeting pending Nasdaq approval of its listing application. The meeting reconvenes Oct. 26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.